Objectives: We describe the emergence and dissemination of multidrug-resistant (MDR) Salmonella Typhimurium in humans, retail meat and food animals from Yucatan, Mexico.
Introduction
During the last two decades, Salmonella enterica subsp. enterica, in particular, serovar Typhimurium, has become increasingly resistant to antimicrobial compounds worldwide. During the 1980s, Salmonella Typhimurium definitive phage type (DT) 104 with resistance to ampicillin, chloramphenicol, streptomycin, sulphonamides and tetracycline (ACSSuT resistance type) emerged in the UK and subsequently disseminated throughout Europe and North America. By the 1990s, Salmonella Typhimurium (both DT 104 and non-DT 104) had acquired additional resistance to trimethoprim-sulfamethoxazole, ciprofloxacin and extended-spectrum cephalosporins (ESCs). 1 Although the ACSSuT phenotype, which is linked to a complex class I integron contained within Salmonella Genomic Island I, was the most prevalent multidrug-resistant (MDR) Salmonella phenotype during the 1980s and 1990s, 1 the recent emergence of MDR Salmonella with AmpC-like ESC resistance represents a new challenge. In North America, this ESC resistance is mediated by a plasmid-borne CMY-2 b-lactamase and has spread horizontally to different serotypes. These plasmids frequently harbour multiple resistance determinants to other antimicrobial classes. The emergence of MDR, ESC-resistant Salmonella is particularly worrisome, because clinicians are left with very few options for effectively treating severe infections. Furthermore, previous studies have shown that antibiotic-resistant Salmonella Typhimurium is associated with an increased frequency of bloodstream infection and mortality. 4, 5 This study is one of the few to describe the emergence and widespread dissemination of MDR bla CMY-2 Salmonella Typhimurium in a developing country such as Mexico, as well as the outcome of affected children.
Materials and methods
We report the results obtained from 2000 to 2005 for an integrated surveillance system of the food chain in Yucatan, Mexico, that included samples from humans, retail meat and food-animal intestines. 6 Sampling of meat and food-animal intestines was designed to reflect regional consumption of each meat product. Data on disease severity and outcome were obtained from the hospital records of children admitted for Salmonella Typhimurium infection. The study was approved by the Hospital General O'Horan Internal Review Board and written informed consent was obtained from all parents or guardians. Statistical testing of differences in proportions was conducted using the x 2 test; P values less than 0.05 were considered significant.
Methods for isolation, identification, susceptibility testing, serotyping and PFGE of Salmonella have been described previously. 6 ESC-resistant Salmonella Typhimurium isolates were subjected to PFGE analysis and examined for the presence of CTX-M, CMY and the combination of SHV, TEM and OXA by PCR, as described by others. 7, 8 DNA sequences were determined and used to screen the GenBank database using the BLAST algorithm available at the National Center of Biotechnology Information's web site (http:// www.ncbi.nlm.nih.gov/BLAST/). Transfer experiments were carried out on a subset of 4 isolates, which were selected from a total of 48 isolates on the basis of distinct plasmid RFLP patterns using PstI. Plasmid DNA was introduced by electroporation into Escherichia coli DH10B (EP-Max 10B) (Invitrogen, Carlsbad, CA, USA), and transformants were selected using ceftriaxone (4.0 mg/ L). Transformed host cells were tested for antimicrobial susceptibility as before and assayed for the acquisition of CMY using PCR.
Results
The number of human, retail meat and food-animal intestine samples positive for Salmonella Typhimurium and MDR bla CMY-2 Salmonella Typhimurium is shown in Table 1 . A total of 2431 Salmonella were recovered from 7206 samples, of which 177 (7.3%) isolates were serovar Typhimurium. Of the 177 Salmonella Typhimurium isolates, 115 (65%) were ESC-resistant. Most of these were recovered from ill children (44.3%) and from pork or swine intestine (36.5%). The prevalence of MDR bla CMY-2 Salmonella Typhimurium among all Salmonella Typhimurium isolates rose from 0% (0/27) during 2000 and 2001 to 75% (63/84) in 2004 and 2005 (P , 0.0001, x 2 for trend). The ceftriaxone MIC 50 and MIC 90 for these isolates were 64 and 128 mg/L, respectively (range 16 to .128 mg/L). In addition to the ACSSuT phenotype, these isolates were non-susceptible to piperacillin, ticarcillin, cefoxitin, ceftazidime, cefotaxime, ceftiofur and aztreonam and did not show increased susceptibility in the presence of clavulanic acid. An important percentage of these strains was also non-susceptible to trimethoprim -sulfamethoxazole (87%), nalidixic acid (58%), gentamicin (44%) and kanamycin (23%) (Figure 1 ). All isolates were susceptible to cefepime, imipenem, ciprofloxacin and amikacin.
Of the 115 ESC-resistant isolates, 113 were available for molecular testing. The bla CMY-2 gene was identified in all of these. With the exception of a single isolate (CVM34474) that also carried TEM-1, none of the other assayed bla genes was detected. The CMY b-lactam resistance phenotype was transferred by electrotransformation of purified plasmid DNA to E. coli DH10 recipient, along with different patterns of resistance to sulfamethoxazole, chloramphenicol, tetracycline, gentamicin, trimethoprim -sulfamethoxazole and kanamycin. For transformant 35417-T, the MIC of ceftriaxone increased 8-fold relative to the wild-type donor strains. Plasmids from this strain type were also distinct in that trimethoprim -sulfamethoxazole, tetracycline and chloramphenicol resistances failed to transfer to the E. coli recipient. PFGE analysis of the 113 MDR bla CMY-2 Salmonella Typhimurium isolates revealed 21 clusters, each of which contained at least two strains with indistinguishable banding patterns. Most of the clusters contained isolates from identical or neighbouring cities. In 8 of the 21 clusters (clusters A-H), human isolates were found to be closely associated with those from swine intestine or retail meat. (Figure 1) .
Clinical charts were available for 63 children with Salmonella Typhimurium infection. Children with MDR bla CMY-2 Salmonella Typhimurium infection (n ¼ 39) had a higher frequency of systemic infection (12.8% versus 0%, P ¼ 0.15), mortality (7.7% versus 0%, P ¼ 0.28) and hospital re-admission due to protracted diarrhoea (28% versus 16.6%, P ¼ 0.46) than children with non-MDR bla CMY-2 Salmonella Typhimurium (n ¼ 24); however, we could not demonstrate statistical significance because of small sample size. Of the children with MDR bla CMY-2 Salmonella Typhimurium infection, two presented severe thrombocytopenia (2000 and 18 000 platelets/ mm 3 , respectively), one of whom died from a cerebral haemorrhage; two other infants died from bloodstream infection.
Discussion
This study documents the emergence and rapid dissemination of MDR bla CMY-2 Salmonella Typhimurium in food animals and humans from Yucatan, Mexico. MDR bla CMY-2 Salmonella Typhimurium has become the predominant phenotype of serovar Typhimurium in the state, currently accounting for 75% of all Salmonella Typhimurium isolates; it is resistant to at least eight antimicrobials and has caused severe enteric and systemic infections in children, three of whom died. Molecular analysis enabled us to presumptively identify swine as the major source of these strains and to determine that ESC-resistance is mediated by a bla CMY-2 gene harboured on different plasmids.
Among food animals, the bla CMY-2 phenotype was only found in swine intestines, suggesting that the main selection pressure for ESC-resistant Salmonella Typhimurium in Yucatan originated and persists in swine production. Its presence in pork, beef and chicken meat is likely due to cross-contamination during slaughter or at retail. Although we made no effort to mobilize them by conjugation, our transformation experiments show that the bla CMY-2 gene resides on plasmids with differing resistance gene content and that they are able to replicate in E. coli. The extent to which CMY dissemination has been mediated by other genera is not known.
In North America, MDR bla CMY-2 salmonellae first emerged in Salmonella Typhimurium and later as part of the multiple resistance genotype in food animal and food-borne isolates of Salmonella Newport. In the USA, bla CMY-2 Salmonella has been primarily associated with cattle and beef, and in Canada, with turkey. 2, 3, 9 Differences in animal reservoirs could be related to food-animal production practices, including the amount and type of antimicrobials used in each country. In both Mexico and the USA, bla CMY-2 Salmonella appears to have established itself in an animal reservoir before spreading to humans.
bla CMY-2 Salmonella is infrequent in countries outside North America, where ESC resistance is more commonly mediated by molecular class A b-lactamases such as TEM, SHV, OXA and CTX. 10 Possible explanations for this low frequency could be differences in the prevalence of specific serovars among countries, the lack of systematic screening for AmpC-type b-lactamase genes in the veterinary sector and cephalosporin usage. Some investigators attribute the emergence of CMY-2 to the use of ceftiofur, a third-generation cephalosporin used exclusively in food animals. 2, 3 Although there are no reliable data in Mexico or the USA on the quantity of third-generation cephalosporins used, these compounds are readily available in veterinary and medical pharmacies throughout Yucatan and can be purchased without prescription (M. Zaidi, unpublished results).
It is noteworthy that systemic Salmonella Typhimurium infection and mortality were only seen in children with MDR bla CMY-2 strains. Moreover, the occurrence of severe thrombocytopenia with haemorrhagic syndrome, a very uncommon presentation of non-typhoidal salmonellosis, should be alerted to all physicians. Although we were unable to demonstrate a statistically significant association between MDR and increased severity of disease, our findings show a clinically significant trend that supports the growing body of literature that associates MDR Salmonella with increased morbidity. 4, 5 In conclusion, our findings highlight the rapid dissemination of MDR CMY-2-producing Salmonella in Mexico, a developing country that currently lacks the infrastructure for effective containment measures. Policy makers need to implement a series of urgent interventions to prevent and control selection of, and environmental contamination with, MDR Salmonella throughout the food chain. Foremost measures include tighter regulations for antimicrobial use and the establishment of an effective surveillance programme to monitor the public health impact of this emerging pathogen.
